Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition
NCT ID: NCT01831674
Last Updated: 2013-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2012-12-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition
NCT01831661
Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition
NCT01160042
Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions
NCT01089179
Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition
NCT01160068
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.
NCT01089192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total duration of the study was of 17 days from the day of admission of first period till the end of second period.
Upon entering into the study, subjects were housed in clinical facility of Veeda Clinical Research Pvt. Ltd. to ensure 10 hours overnight fasting before dosing and continued to be housed in the facility till 36.00 hours post-dose blood sample collection in each of the two periods.
A gap of 14 days was kept as wash out between each consecutive dosing period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin Hydrochloride Extended-Release Tablets USP 750
Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
Metformin Hydrochloride Extended-Release Tablets USP 750
Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
GLUCOPHAGE®XR tablet 750 mg
GLUCOPHAGE®XR 750 mg once a day
GLUCOPHAGE®XR
GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
Metformin Hydrochloride Extended-Release Tablets USP 750
Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
GLUCOPHAGE®XR tablet 750 mg
GLUCOPHAGE®XR 750 mg once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin Hydrochloride Extended-Release Tablets USP 750
Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
GLUCOPHAGE®XR tablet 750 mg
GLUCOPHAGE®XR 750 mg once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects' weight within normal range according to normal values for Body Mass Index (18.5 to 24.9 kg/m2) (including both) with minimum of 50 kg weight.
3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range.
4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
5. Subjects having clinically acceptable chest X-Ray (PA view).
6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
7. Subjects having negative alcohol breathe test.
8. Subjects willing to adhere to protocol requirements and to provide written informed consent.
9. Subjects having negative Beta-hCG Pregnancy test (only for female subjects).
10. For Female Subjects:
1\) Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence, or 2) Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above 3) Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).
Exclusion Criteria
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting
4. History or Presence of significant alcoholism or drug abuse.
5. History or presence of significant asthma, urticaria or other allergic reactions.
6. History or presence of significant gastric and/or duodenal ulceration.
7. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
8. History or presence of cancer.
9. History or presence of significant easy bruising or bleeding.
10. History or presence of significant recent trauma.
11. Subjects who have been on an abnormal diet (for whatever reason) during four weeks preceding the study.
12. Difficulty with donating blood.
13. Difficulty in swallowing solids like tablets or capsules.
14. Use of any prescribed or OTC medication during last two weeks prior to dosing in period 01.
15. Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol within 48 hours prior to dosing.
16. Major illness during 3 months before screening.
17. Participation in a drug research study within past 3 months.
18. Donation of blood from past 3 months before screening.
19. Female subjects who are currently breast feeding.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IPCA Laboratories Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Hardik Dave, M.B.B.S
Role: PRINCIPAL_INVESTIGATOR
Veeda Clinical Research Pvt. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Veeda Clinical Research Pvt. Ltd.
Ahmedabad, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-VIN-184
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.